English
Regional settings| Spread | 0.10 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 6.1 |
| Open | 5.93 |
| 1-Year Change | 81.9% |
| Day's Range | 5.71 - 6.05 |
LifeVantage Corporation is engaged in the business of identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath & body, and targeted relief products. Its products include Protandim, LifeVantage Omega+, ProBio and Daily Wellness dietary supplements, TrueScience, Axio and PhysIQ. LifeVantage Omega+ is a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3 to support cognitive health, cardiovascular health, skin health, and the immune system. ProBio is a dietary supplement designed to support optimal digestion and immune system function. Daily Wellness is a dietary supplement designed to support and strengthen immune health. TrueScience, which consists of facial cleanser, perfecting lotion, eye serum. PhysIQ, which consists of fat burn, prebiotic and whey protein.
BRIEF: For the six months ended 31 December 2021, LifeVantage Corp revenues decreased 7% to $105.4M. Net income decreased 46% to $3.4M. Revenues reflect Americas segment decrease of 12% to $71.2M. Net income also reflects Foreign Exchange Gain/Loss–Non-Business decrease from $200K (income) to $300K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $0.44 to $0.25.
Common Stock, $.001 Par, 08/11, 250M auth., 73,518,592 issd.Insiders & stakeholders own 6.72%. 9/28/2004, 68-for-1 Stock Split. Common Stock, Series B $.001, 250M auth., none issd. Name changed from Yaak Resources, Inc. 12/06, Name changed from Lifeline Therapeutics, Inc. 10/15, 1-for-7 reverse stock split.
